Inhaled Drugs and Systemic Corticosteroids for Bronchopulmonary Dysplasia

被引：7

作者：

Bassler, Dirk ^{[1
]}

van den Anker, John ^{[2
,3
]}

机构：

[1] Univ Zurich, Univ Hosp Zurich, Dept Neonatol, Frauenklin Str 10, CH-8091 Zurich, Switzerland

[2] Univ Basel, Div Paediat Pharmacol & Pharmacometr, Childrens Hosp, Spitalstr 33, CH-4056 Basel, Switzerland

[3] Childrens Natl Med Ctr, Div Clin Pharmacol, 111 Michigan Ave NorthWest, Washington, DC 20010 USA

来源：

PEDIATRIC CLINICS OF NORTH AMERICA | 2017年 / 64卷 / 06期

关键词：

Bronchopulmonary dysplasia; Inhaled corticosteroids; Inhaled bronchodilators; Systemic corticosteroids; Dexamethasone; Hydrocortisone; Pharmacology; CHRONIC LUNG-DISEASE; LOW-DOSE HYDROCORTISONE; PRETERM INFANTS; PREMATURE-INFANTS; RANDOMIZED-TRIAL; CEREBRAL-PALSY; DOUBLE-BLIND; PREVENTION; THERAPY; PHARMACOKINETICS;

D O I：

10.1016/j.pcl.2017.08.012

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

All definitions of bronchopulmonary dysplasia (BPD) have limitations, and a new definition for the purpose of clinical research, benchmarking, and prognostic prediction is needed. Different inhaled and systemic drugs are currently used to prevent or treat BPD. Despite some positive effects on BPD, more information about the effects of inhaled corticosteroids is required to assess overall efficacy and associated risks. One needs to balance the risks of neurodevelopmental impairment owing to systemic corticosteroids against those of BPD itself. Future studies should, therefore, focus on infants with a very high risk of developing BPD and include pharmacokinetics and long-term developmental outcomes.

引用

页码：1355 / +

页数：14

共 50 条

[31] Inhaled budesonide for the prevention of bronchopulmonary dysplasia
Bassler, Dirk
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2017, 30 (19): : 2372 - 2374
[32] TREATMENT OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS WITH INHALED CORTICOSTEROIDS
BALTER, MS
REBUCK, AS
RESPIRATORY MEDICINE, 1992, 86 (05) : 441 - 442
[33] Late (≥7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
Doyle, Lex W.
Cheong, Jeanie L.
Hays, Susanne
Manley, Brett J.
Halliday, Henry L.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (11):
[34] Late (æ7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
Doyle, Lex W.
Cheong, Jeanie L.
Ehrenkranz, Richard A.
Halliday, Henry L.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (10):
[35] Early (∼ 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
Doyle, Lex W.
Cheong, Jeanie L.
Ehrenkranz, Richard A.
Halliday, Henry L.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (10):
[36] Orphan drugs in bronchopulmonary dysplasia
Greenough, Anne
Bhat, Prashanth
EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (05): : 351 - 358
[37] SYSTEMIC EFFECTS OF INHALED CORTICOSTEROIDS
MONSON, JP
THORAX, 1993, 48 (10) : 955 - 956
[38] Systemic effects of inhaled corticosteroids
Harrison, TW
Tattersfield, AE
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (07) : 1037 - 1038
[39] Systemic effects of inhaled corticosteroids
Ernst, Pierre
Suissa, Samy
CURRENT OPINION IN PULMONARY MEDICINE, 2012, 18 (01) : 85 - 89
[40] Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia
Doyle, Lex W.
NEONATOLOGY, 2021, 118 (02) : 244 - 251

← 1 2 3 4 5 →